Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) and Solana (NASDAQ:HSDT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Profitability
This table compares Tandem Diabetes Care and Solana’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tandem Diabetes Care | -20.17% | -68.23% | -11.07% |
| Solana | -39,358.88% | -699.93% | -301.82% |
Risk and Volatility
Tandem Diabetes Care has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Solana has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tandem Diabetes Care | 1 | 11 | 6 | 1 | 2.37 |
| Solana | 1 | 0 | 0 | 0 | 1.00 |
Tandem Diabetes Care currently has a consensus price target of $28.00, suggesting a potential upside of 7.65%. Given Tandem Diabetes Care’s stronger consensus rating and higher probable upside, analysts clearly believe Tandem Diabetes Care is more favorable than Solana.
Insider & Institutional Ownership
18.6% of Solana shares are owned by institutional investors. 1.9% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 17.2% of Solana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Tandem Diabetes Care and Solana”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tandem Diabetes Care | $1.01 billion | 1.75 | -$204.71 million | ($3.07) | -8.47 |
| Solana | $520,000.00 | 172.35 | -$11.74 million | ($1,267.04) | 0.00 |
Solana has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.
Summary
Tandem Diabetes Care beats Solana on 10 of the 15 factors compared between the two stocks.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
About Solana
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
